Oncology

Prostate cancer cells
#Oncology #Phase II trial #Promontory Therapeutics #Prostate cancer

Prostate cancer drug shows ‘promising’ mechanism of action

Pharmaceutical company Promontory Therapeutics has completed enrolment of its Phase II clinical trial of lead therapeutic candidate, PT-112, in patients with late-line metastatic castration-resistant prostate cancer (mCRPC). The study is evaluating PT-112 in patients who have been treated with at least three prior life-prolonging therapies… Read More

#Cancer Research #News

Acute myeloid leukaemia
#Acute Myeloid Leukaemia #Blood cancer #Daiichi Sankyo #MHRA #Oncology

UK approves quizartinib for FLT3-ITD-positive AML

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults with acute myeloid leukaemia (AML). Each year in the UK around 3,100 people are diagnosed with AML. Julian… Read More

#News #Regulatory

T cells attacking cancer
#CAR-T #Elicera Therapeutics #Lung cancer #Oncology #Partnership #Skin cancer #T cell receptor (TCR)

Collaborators investigate novel T-cell receptor therapy

Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer. Elicera Therapeutics will make parts of its technology iTANK available to… Read More

#Cancer Research #News

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

New DDW Highlights podcast: 11 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was antibodies hitting the headlines this week, with the discovery of antibodies with… Read More

#News

CRISPR gene editing
#CRISPR #CRISPR-Cas9 #Gene editing #HPV #Immunotherapy #iPSC #Oncology

Discovery paves the way to ‘off-the-shelf’ cervical cancer therapy

Researchers from Japan have used CRISPR gene editing to enhance the effectiveness of rejuvenated cytotoxic T lymphocytes (rejTs) for targeted immunotherapy. RejTs constitute a promising approach for treating cervical cancer, though rejection by the host’s immune system is a major hurdle. In a recent… Read More

#Cancer Research #Editor's Choice #News

Pancreatic cancer
#FDA #Fibrosis #iOnctura #Oncology #Orphan drugs #Pancreatic cancer

Orphan Drug Designation for first-in-class autotaxin cancer therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to iOnctura for its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. After assessing its novel chemical and biological properties, including an attractive non-clinical safety and efficacy profile, the FDA has granted… Read More

#Cancer Research #News #Regulatory

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

This week in drug discovery (4-8 March) 

News round-up for 4-8 March by DDW Digital Content Editor Diana Spencer. It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and… Read More

#News

#Artificial intelligence (AI) #Cancer Research UK #Oncology #Prostate cancer #University of East Anglia #University of Oxford

AI reveals prostate cancer is not just one disease

Research published in Cell Genomics has shown that prostate cancer includes two different subtypes of the disease, also known as evotypes. This discovery was made by using artificial intelligence (AI) to help unlock new discoveries about the evolution of prostate cancer and could lead to the… Read More

#Cancer Research #News #Trending News

Antibodies
#Antibodies #Oncology #Phase I trial #Solid tumours

Antibody therapy shows anti-tumour activity in advanced cancer

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells. CS1002 increases the activation and proliferation of… Read More

#Cancer Research #News

FDA
#Adverse event #FDA #Myeloma #Oncology #Oncopeptides

FDA withdraws approval of Oncopeptides’ Pepaxto

The US Food and Drug Administration (FDA) has announced its final decision to withdraw approval of Pepaxto (melphalan flufenamide), despite an appeal by manufacturer Oncopeptides. The drug was originally approved for use in combination with dexamethasone to treat some patients with multiple myeloma. Approval… Read More

#News #Regulatory #Trending News

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #Gene expression #Gene mutation #Interview #mRNA #Next generation sequencing #Oncology #PharmEnable #RNA sequencing #Single-cell RNA sequencing #Vaccines

Podcast: What trends will speed up the journey from clinic to bedside?

This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More

#News

Scientist in modern laboratory
#Cancer research #Clinical trial #CureLab Oncology #Oncology #Phase I trial

Study undermines mechanism-based discovery, says CureLab

CureLab Oncology’s DNA vaccine Elenagen, in combination with chemotherapy, has demonstrated promising clinical results against triple-negative ovarian cancer. The study shows that disease progression was significantly delayed in a group of stage III and IV platinum-resistant ovarian cancer (PROC) patients who received gemcitabine in combination with… Read More

#Cancer Research #Editor's Choice #News

CAR-T therapy
#CAR-T #Cell therapy #CHMP #European Medicines Agency #Myeloma #Oncology

CAR-T therapy recommended for melanoma after first relapse

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the earlier treatment of relapsed and refractory multiple myeloma (RRMM). The recommended indication for cilta-cel… Read More

#News #Regulatory

Doctor prepares vaccine
#Cancer vaccine #Genetic diseases #ImmunityBio #Immunology / Virology & Vaccines #Oncology #Phase II trial

Combination cancer vaccine to be assessed in Phase II trial

The first 20 participants have been enrolled in a multicentre trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) could potentially prevent colon and other cancers in individuals with Lynch syndrome. The vaccine comprises a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803. Read More

#Cancer Research #News

#Artificial intelligence (AI) #Cancer research #Immunotherapy #Machine learning #Oncology #Spatial biology

The biotech improving immunotherapies with AI

DDW Editor Reece Armstrong speaks to Ron Alfa, CEO & Co-founder at NOETIK, about the company’s mission to utilise artificial intelligence (AI) and spatial biology to develop better immunotherapies for cancer patients. Reece A: What are some of the human limitations to current drug discovery research for immunotherapies?… Read More

#Cancer Research #Exclusive Content